|
Recent Newsletters
Structural Heart Disease Highlights: 10 reasons heart teams may consider SAVR over TAVR | ACC late-breakers |
Key takeaways from ACC.23 | How to anticoagulate COVID patients | Links to all the ACC late-breaking trials |
Heart Failure Highlights: The limited the value of dapagliflozin & empagliflozin | FDA rules on omecamtiv mecarbil |
Heart inflammation seen in some patients 2 months after vaccination | Early menopause & TAVR outcomes |
Cardiologist violently attacked | Keto-like diets & heart disease | ACC.23 | More from the last week |
Cardiologists send warning to the White House | ACC.23 seen as a return to normalcy | SGLT2 inhibitors & HF |
Keto diets linked to high cholesterol, CVD | New ACC president shares his vision | Cardiologist violently attacked |